Paul A. Hamlin

8.1k citations

155 papers · 4.0k indexed · h-index 33

Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment 128
Genetics top 1%
- Chronic Lymphocytic Leukemia Research 61
Oncology top 1%
- Viral-associated cancers and disorders 32
- CAR-T cell therapy research 10
Neurology top 1%
- CNS Lymphoma Diagnosis and Treatment 30
Dermatology top 1%
- Cutaneous lymphoproliferative disorders research 16
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 18
Immunology
- T-cell and Retrovirus Studies 10

Co-authors: Andrew D. Zelenetz Craig H. Moskowitz David J. Straus Carol S. Portlock Ariela Noy Steven M. Horwitz Owen A. O’Connor Joachim Yahalom
Cited by: Pathology and Forensic Medicine Genetics Oncology
Journals: Blood (62 papers)Journal of Clinical Oncology (29 papers)British Journal of Haematology (10 papers)
Partner nations: United States France Germany

In The Last Decade

Paul A. Hamlin

146 papers receiving 3.9k citations

Peers

Countries citing papers authored by Paul A. Hamlin

Since Specialization

Citations

This map shows the geographic impact of Paul A. Hamlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul A. Hamlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul A. Hamlin more than expected).

Fields of papers citing papers by Paul A. Hamlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul A. Hamlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul A. Hamlin. The network helps show where Paul A. Hamlin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Paul A. Hamlin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul A. Hamlin Line = papers co-authored together Paul A. Hamlin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP Blood Advances ·V. Chizchova,Alexandra N. Smith,Matthew J. Maurer,Julie Teruya‐Feldstein,Matthew J. Matasar,Alison J. Moskowitz,David J. Straus,Ariela Noy,M. Lia Palomba,Steven M. Horwitz,Paul A. Hamlin,Carol S. Portlock,James R. Cerhan,Thomas M. Habermann,Gilles Salles,Grzegorz S. Nowakowski,Craig H. Moskowitz,Andrew D. Zelenetz	2024	2
2	CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas PubMed ·Paola Ghione,V. Chizchova,Erel Joffe,M. Lia Palomba,Ariela Noy,Philip Caron,Paul A. Hamlin,Anita Kumar,Matthew J. Matasar,Colette Owens,Alison J. Moskowitz,Lorenzo Falchi,David J. Straus,Steven M. Horwitz,Gilles Salles,Ahmet Doǧan,Andrew D. Zelenetz	2024	1
3	A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma Leukemia & lymphoma ·Christopher A. V. Swendris,V. Chizchova,Paul A. Hamlin,Anita Kumar,Matthew J. Matasar,Menglei Zhu,Laura Miranda Mairal,Nageshwar Rao,Pilar Zuloaga,Gilles Salles,Andrew D. Zelenetz,Gottfried von Keudell	2024	0
4	Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma - International, Multi-Center Real-World Experience Blood ·Efrat Luttwak,Alencar Cordeiro Ridolphi,Esther Drill,Nivetha Ganesan,Devorah Schoenfeld,Ronit Gurion,Shlomzion Aumann,Takenori Matsuda,Rubee Chanu Thangjam,Viviane Z. Costa,Robert Stuver,Paul A. Hamlin,Ariela Noy,Alex F. Herrera,Alison J. Moskowitz	2024	0
5	Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design Leukemia & lymphoma ·Anita Kumar,Carla Casulo,Erel Joffe,Craig H. Moskowitz,John F. Gerecitano,Alison J. Moskowitz,Anas Younes,Pamela Drullinsky,Esther Drill,河島尚志,正蓑輪,Laura Miranda Mairal,Greta Guogaitė,Ariën de Klerk,Andrew D. Zelenetz,Paul A. Hamlin	2022	1
6	Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue Blood Advances ·Erel Joffe,Yan Leyfman,Esther Drill,Usman Abdullahi,Andrew D. Zelenetz,M. Lia Palomba,Craig H. Moskowitz,Carol S. Portlock,Ariela Noy,Steven M. Horwitz,John F. Gerecitano,Alison J. Moskowitz,Paul A. Hamlin,Matthew J. Matasar,Anita Kumar,Connie Lee Batlevi,Anas Younes,David J. Straus	2021	7
7	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma Blood ·Sven Borchmann,Erel Joffe,Craig H. Moskowitz,Andrew D. Zelenetz,Ariela Noy,Carol S. Portlock,John F. Gerecitano,Connie Lee Batlevi,Philip Caron,Pamela Drullinsky,Audrey Hamilton,Paul A. Hamlin,Steven M. Horwitz,Anita Kumar,Matthew J. Matasar,Alison J. Moskowitz,Colette Owens,M. Lia Palomba,Anas Younes,David J. Straus	2019	26
8	Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse Blood Cancer Journal ·Anita Kumar,Fushen Sha,Ahmed Toure,Ahmet Doǧan,Ai Ni,Connie Lee Batlevi,Maria Lia Palomba,Carol S. Portlock,David J. Straus,Ariela Noy,Steven M. Horwitz,Alison J. Moskowitz,Paul A. Hamlin,Craig H. Moskowitz,Matthew J. Matasar,Andrew D. Zelenetz,Anas Younes	2019	76
9	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma Journal of Clinical Oncology ·Andrew M. Evens,Ranjana H. Advani,Irene Helenowski,Michelle A. Fanale,Sonali M. Smith,Borko Jovanovic,Gregory Bociek,Andreas K. Klein,Jane N. Winter,Leo I. Gordon,Paul A. Hamlin	2018	96
10	Prospective Study of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma Journal of Nuclear Medicine ·Heiko Schöder,Andrew D. Zelenetz,Paul A. Hamlin,Somali Gavane,Steven M. Horwitz,Matthew J. Matasar,Alison J. Moskowitz,Ariela Noy,Lia Palomba,Carol S. Portlock,David J. Straus,Ravinder K. Grewal,Jocelyn Migliacci,Steven M. Larson,Craig H. Moskowitz	2015	30
11	Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary Annals of Oncology ·V. A. Morrison,Paul A. Hamlin,Pierre Soubeyran,Reinhard Stauder,Punit D. Wadhwa,Matti Aapro,Stuart M. Lichtman	2015	50
12	Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma Journal of Clinical Oncology ·Craig H. Moskowitz,Heiko Schöder,Julie Teruya‐Feldstein,Camelia S. Sima,Alexia Iasonos,Carol S. Portlock,David J. Straus,Ariela Noy,Maria Lia Palomba,Owen A. O’Connor,Steven M. Horwitz,Sarah A. Weaver,Doreen Richardson,Daniel A. Filippa,James F. Caravelli,Paul A. Hamlin,Andrew D. Zelenetz	2010	225
13	Is Maintenance Rituximab Now Ready for PRIMA-Time? Current Oncology Reports ·Paul A. Hamlin	2010	2
14	High‐dose chemo‐radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre‐transplant functional imaging British Journal of Haematology ·Craig H. Moskowitz,Joachim Yahalom,Andrew D. Zelenetz,Zhigang Zhang,Daniel A. Filippa,Julie Teruya‐Feldstein,Tarun Kewalramani,Alison J. Moskowitz,Robert D. Rice,Jocelyn Maragulia,Jill Vanak,Tanya Trippett,Paul A. Hamlin,S. Horowitz,Ariela Noy,Owen A. O’Connor,Carol S. Portlock,David J. Straus,Stephen D. Nimer	2010	59
15	Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies Journal of Clinical Oncology ·Owen A. O’Connor,Steven M. Horwitz,Paul A. Hamlin,Carol S. Portlock,Craig H. Moskowitz,Debra Sarasohn,Ellen Neylon,Liu JianRong,Marc A. McWilliams,Barbara MacGregor‐Cortelli,Molly Bruce Patterson,Venkatraman Seshan,L. M. HARROD,Martin Fleisher,Diane R. Mould,M.I. Saunders,Andrew D. Zelenetz	2009	131
16	Distress in Older Patients With Cancer Journal of Clinical Oncology ·Arti Hurria,Daneng Li,Kurt Hansen,Sujata Patil,Ravi Gupta,Christian J. Nelson,Stuart M. Lichtman,William P. Tew,Paul A. Hamlin,Enid Zuckerman,Agnieszka Lodowska,Sewanti Limaye,Mark S. Lachs,István Szakadát	2009	101
17	The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL) Annals of Oncology ·Ariela Noy,Heiko Schöder,Mithat Gönen,Torabi Ali,Lukman Yudho,Johnson Jennifer,C. Portlock,Paul A. Hamlin,Henry Yeung	2009	107
18	Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population Annals of Oncology ·Michaela Liedtke,Paul A. Hamlin,Craig H. Moskowitz,Andrew D. Zelenetz	2006	71
19	Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphoma British Journal of Haematology ·Tarun Kewalramani,Andrew D. Zelenetz,Julie Teruya‐Feldstein,Paul A. Hamlin,Joachim Yahalom,Steven M. Horwitz,Stephen D. Nimer,Craig H. Moskowitz	2006	83
20	Pralatrexate (10-Propargyl-10-Deazaaminopterin (PRX)), a Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients with a Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity. Blood ·州弘宮崎,Paul A. Hamlin,Ellen Neylon,Craig H. Moskowitz,C. Portlock,Fatih İYİYOL,Ariela Noy,Kyung-Eun Lee,Andrew D. Zelenetz,Martin Fleisher,Debra Sarasohn,F. M. Sirotnak,Kulich Ni	2005	6

About Paul A. Hamlin

Paul A. Hamlin is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology, having authored 155 papers that have together received 4.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (128 papers), Chronic Lymphocytic Leukemia Research (61 papers), Viral-associated cancers and disorders (32 papers), CNS Lymphoma Diagnosis and Treatment (30 papers), Lung Cancer Treatments and Mutations (18 papers), Cutaneous lymphoproliferative disorders research (16 papers), T-cell and Retrovirus Studies (10 papers) and CAR-T cell therapy research (10 papers). The work is most often cited by research in Pathology and Forensic Medicine (2.9k citations), Genetics (925 citations) and Oncology (2.0k citations). Paul A. Hamlin has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Andrew D. Zelenetz, Craig H. Moskowitz, David J. Straus, Carol S. Portlock, Ariela Noy, Steven M. Horwitz, Owen A. O’Connor, Joachim Yahalom, Stephen D. Nimer and Tarun Kewalramani. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Annals of Oncology and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact